February 23, 2018 02:46 PM IST An IIFL report quotes the management of Strides Shasun as saying that pharmaceutical benefits scheme price cuts have bottomed out. In an interview to CNBC-TV18, Shashank Sinha, MD of the company spoke about the same and gave his outlook for the future.
December 24, 2017 10:07 AM IST Jay Purohit, Technical & Derivatives Analyst at Centrum Broking Limited, says short-term traders are advised to book some profit at current levels.
September 25, 2017 04:07 PM IST In an interview to CNBC-TV18, Shashank Sinha, MD & GROUP CEO of Strides Shasun spoke about the latest happenings in his company and sector.
July 17, 2017 12:33 PM IST Strides Shasun may receive approval for Lovaza generic, which has a market size of around USD 750-800 million in the United Sates and could make upto USD 200 million annually for the company. There has been a lot of buzz around pending application for Omega 3 which is the generic version of Lovaza, Shashank Sinha, MD & Group CEO of Strides Shasun told CNBC-TV18.
July 03, 2017 02:26 PM IST Competition Commission of India (CCI) approves Scheme of Arrangement between Strides Shasun, Sequent Scientific and Solara Active Pharma Sciences. In an interview to CNBC-TV18, Manish Gupta, CEO of Sequent Scientific spoke about the same.
November 03, 2016 11:42 AM IST There was some regulatory overhangs post Strides-Mylan Agila transaction, says Arun Kumar, Executive VC & MD of Strides Shasun.
September 09, 2016 10:30 PM IST In an interview to CNBC-TV18, Arun Kumar, Founder & MD of Strides Shasun says that the pharma industry lacks trust now as more and more issues with regulators come to light.
August 11, 2015 12:33 PM IST Abhaya Kumar, MD at Shasun Pharmaceuticals said the company's merger with Strides will be completed as soon as court approvals of the latter are in place. He is sure the merged entity will be effective from April 1 2015 itself.
May 21, 2015 01:02 PM IST The new business will operate under Arrow Pharma and sell 140 generic drugs. The transaction will be financed by internal accruals and debt financing. The acquisition will be EPS accretive immediately.
December 10, 2013 02:01 PM IST Strides Arcolab has a fairly strong organic growth strategy in place at the moment, says Group CEO & VC Arun Kumar.
September 05, 2013 01:32 PM IST Given the fact that US gets 35 percent of its drugs from India, the regulator is only doing its job in looking closely at not just India's, but other countries‘ pharma units too, adds Ramesh Adige, former executive director, Ranbaxy.
April 17, 2013 01:28 PM IST Strides Arcolab‘s subsidiary Agila Biotech has signed a joint venture agreement with US-based Pfenex for developing, manufacturing and commercializing six biosimilar products for the global market
January 24, 2012 04:00 PM IST Strides Arcolab aims to use the funds received through the sale of its Southeast Asian and Australian units to repay foreign currency convertible bondholders and reduce the debt, says group chief executive and vice chairman Arun Kumar.
July 01, 2011 12:53 PM IST In an interview with CNBC-TV18, Arun Kumar, Vice Chairman and MD, Strides Arcolab said Polymyxin is a small molecule, but currently it is in the shortage list of products. He further said the company will grow 30-35% in the current year.
May 02, 2011 12:58 PM IST Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings in the next few weeks.
March 01, 2011 04:41 PM IST In an interview with CNBC-TV18, Arun Kumar, Group CEO and Vice Chairman, Strides Arcolab spoke on the development and the way forward for the company.
